October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 24, 2025

Synbiotic Supplement Reduced Multiple Inflammatory Proteins

Butyrate rise corresponded with lower IL-6 during 6-week synbiotic supplementation.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 23, 2025

Is the Estradiol Ring Losing Strength Early?

Patients reported return of vasomotor symptoms before the 3-month mark in real-world use. 

Conexiant

October 22, 2025

Primary Care Workload: 62 Hours Weekly

Electronic records detail physician work hours across multiple primary care clinics.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant